



LEI: 549300Q7EXQQH6KF7Z84

9 June 2025

**RTW BIOTECH OPPORTUNITIES LTD**  
**(the "Company")**

**Results of the Annual General Meeting ("AGM")**

The Company is pleased to announce that, at the sixth AGM held at 14.00 BST today, 9 June 2025, each of the Resolutions was duly passed without amendment.

The details of each resolution are as follows:

**ORDINARY RESOLUTIONS**

Resolution 1

**IT WAS RESOLVED** to receive and consider the Audited Financial Statements, the Directors' report, and the auditor's report for the financial year ended 31 December 2024.

For	149,172,488 votes
Against	1,607 votes
Withheld	16,084 votes

Resolution 2

**IT WAS RESOLVED** to approve the Directors' remuneration for the financial year ended 31 December 2024 as provided in the Directors' report.

For	149,065,933 votes
Against	99,493 votes
Withheld	24,753 votes

Resolution 3<sup>1</sup>

**IT WAS RESOLVED** to re-elect William Simpson as a Director of the Company.

For	480,796,845 votes
Against	22,288 votes
Withheld	34,696 votes

Resolution 4<sup>1</sup>

**IT WAS RESOLVED** to re-elect Paul Le Page as a Director of the Company.

For	480,787,459 votes
Against	32,443 votes
Withheld	33,927 votes

Resolution 5<sup>1</sup>

**IT WAS RESOLVED** to re-elect Bill Scott as a Director of the Company.

For	480,409,211 votes
Against	410,691 votes
Withheld	33,927 votes

Resolution 6<sup>1</sup>

**IT WAS RESOLVED** to re-elect Baroness Nicola Blackwood as a Director of the Company.

For	480,797,614 votes
Against	22,726 votes
Withheld	33,489 votes

Resolution 7

**IT WAS RESOLVED** to re-elect Stephanie Sirota as a Director of the Company.

For	147,555,370 votes
-----	-------------------

For	141,553,219 votes
Against	1,600,642 votes
Withheld	34,258 votes

#### Resolution 8

**IT WAS RESOLVED** to re-appoint KPMG Channel Islands Limited and KPMG LLP as Auditor of the Company.

For	149,139,600 votes
Against	27,622 votes
Withheld	22,957 votes

#### Resolution 9

**IT WAS RESOLVED** to authorise the Board of Directors to determine the remuneration of the Auditor.

For	149,156,787 votes
Against	13,246 votes
Withheld	20,146 votes

#### **As Special business**

#### Resolution 10

**IT WAS RESOLVED** That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that:

- i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 49,896,260 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares);
- ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US 0.01;
- iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and

such authority to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2026 (unless previously renewed, revoked or varied by the Company by ordinary resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract.

For	149,142,357 votes
Against	27,676 votes
Withheld	20,146 votes

Responses to investors' questions will be posted on the Company's website after the AGM.

<sup>1</sup> The Company notes that the voting rights adjustments under Article 6 and Article 23 of the Company's Articles of Incorporation were used in respect of resolutions 3, 4, 5 and 6, but this did not affect the outcome of the shareholder vote.

\*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolution.

#### **Enquiries:**

**RTW Investments, LP - Investment Manager** +44 (0)20 7959 6361  
 Woody Stileman (Business Development) biotechopportunities@rtwfunds.com  
 Oliver Kenyon (Business & Corporate Development)  
 Krisha McCune (Investor Relations)

**Deutsche Numis - Joint Corporate Broker** +44 (0)20 7260 1000  
 Freddie Barnfield  
 Nathan Brown  
 Euan Brown

#### **About RTW Biotech Opportunities Ltd:**

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at [www.rtwfunds.com/rtw-biotech-opportunities-ltd](http://www.rtwfunds.com/rtw-biotech-opportunities-ltd) for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGEALKNELASEFA